Identification of Cross-Reactive CD8+ T Cell Receptors with High Functional Avidity to a SARS-CoV-2 Immunodominant Epitope and Its Natural Mutant Variants

Chao Hu,Meiying Shen,Xiaojian Han,Qian Chen,Luo Li,Siyin Chen,Jing Zhang,Fengxia Gao,Wang,Yingming Wang,Tingting Li,Shenglong Li,Jingjing Huang,Jianwei Wang,Ju Zhu,Dan Chen,Qingchen Wu,Kun Tao,Da Pang,Aishun Jin
DOI: https://doi.org/10.1016/j.gendis.2021.05.006
IF: 7.376
2022-01-01
Genes & Diseases
Abstract:Despite the growing knowledge of Tcell responses in COVID-19 patients,there is a lack of detailed characterizations for T cell-antigen interactions and T cell functions.Here,with a predicted peptide library from SARS-CoV-2 S and N proteins,we found that specific CD8+T cell responses were identified in over 75%of COVID-19 convalescent pa-tients(15/20)and an epitope from the N protein,N361-369(KTFPPTEPK),was the most domi-nant epitope from our selected peptide library.Importantly,we discovered 2 N361-369-specific T cell receptors(TCRs)with high functional avidity that were independent of the CD8 co-receptor.These TCRs exhibited complementary cross-reactivity to several presently reported N361-369 mutant variants,as to the wild-type epitope.Further,the nat-ural functions of these TCRs in the cytotoxic immunity against SARS-CoV-2 were determined with dendritic cells(DCs)and the lung organoid model.We found that the N361-369 epitope could be normally processed and endogenously presented by these different types of anti-gen presenting cells,to elicit successful activation and effective cytotoxicity of CD8+T cells ex vivo.Our study evidenced potential mechanisms of cellular immunity to SARS-CoV-2,and illuminated potential ways of viral clearance in COVID-19 patients.These re-sults indicate that utilizing CD8-independent TCRs against SARS-CoV-2-associated antigens may provide functional superiority that is beneficial for the adoptive cell immunotherapies based on natural or genetically engineered T cells.Additionally,this information is highly relevant for the development of the next-generation vaccines with protections against continuously emerged SARS-CoV-2 mutant strains.
What problem does this paper attempt to address?